RVMD - Revolution Medicines - Stock Forecast

Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

RVMD is currently covered by 12 analysts with an average price target of $58.81. This is a potential upside of $19.04 (47.88%) from yesterday's end of day stock price of $39.77.

Revolution Medicines's activity chart (see below) currently has 48 price targets and 102 ratings on display. The stock rating distribution of RVMD is 100% BUY.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 77.5% with an average time for these price targets to be met of 305.86 days.

Highest price target for RVMD is $82, Lowest price target is $55, average price target is $65.

Most recent stock forecast was given by ROBERT BURNS from HC WAINWRIGHT on 14-May-2025. First documented stock forecast 09-Mar-2020.

Currently out of the existing stock ratings of RVMD, 66 are a BUY (100%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$72

$32.23 (81.04%)

$73

10 days ago
(14-May-2025)

16/20 (80%)

$32.52 (82.37%)

315

Buy

$57

$17.23 (43.32%)

$59

16 days ago
(08-May-2025)

11/20 (55%)

$15.09 (36.01%)

118

Buy

$75

$35.23 (88.58%)

$60

16 days ago
(08-May-2025)

8/9 (88.89%)

$33.09 (78.95%)

142

Buy

$80

$40.23 (101.16%)

$87

16 days ago
(08-May-2025)

2/4 (50%)

$38.09 (90.89%)

542

Buy

$67

$27.23 (68.47%)

$67

26 days ago
(28-Apr-2025)

4/6 (66.67%)

$25.53 (61.56%)

101

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is RVMD (Revolution Medicines) average time for price targets to be met?

On average it took 305.86 days on average for the stock forecasts to be realized with a an average price target met ratio 77.5

Which analyst has the current highest performing score on RVMD (Revolution Medicines) with a proven track record?

MICHAEL SCHMIDT

Which analyst has the most public recommendations on RVMD (Revolution Medicines)?

Michael Schmidt works at GUGGENHEIM and has 5 price targets and 3 ratings on RVMD

Which analyst is the currently most bullish on RVMD (Revolution Medicines)?

Michael Schmitz with highest potential upside - $42.23

Which analyst is the currently most reserved on RVMD (Revolution Medicines)?

Chris Shibutani with lowest potential downside - -$16.77

Revolution Medicines in the News

Q1 2025 Revolution Medicines Inc Earnings Call

Participants Ryan Asay; Senior Vice President – Corporate Affairs; Revolution Medicines Inc Mark Goldsmith; Chairman of the Board, President, Chief Executive Officer; Revolution Medicines Inc Steve Kelsey; President – Research and Development; Revolution Medicines Inc Wei Lin; Chief Medical Officer; Revolution Medicines Inc Jack Anders; Chief Financial Officer; Revolution Medicines Inc Michael Schmidt; Analyst; Guggenheim...

Revolution Medicines Inc (RVMD) Q1 2025 Earnings Call Highlights: Strategic Advances Amid ...

Cash and Investments: $2.1 billion as of the end of Q1 2025. R&D Expenses: $205.7 million for Q1 2025, up from $118 million in Q1 2024. G&A Expenses: $35 million for Q1 2025, compared to $22.8 million in Q1 2024. Net Loss: $213.4 million for Q1 2025, compared to $116 million in Q1 2024. Projected...

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?